AnaptysBio, Inc. - Special Call

Core Viewpoint - Anaptys plans to separate its biopharma operations from its royalty assets to maximize value by creating two distinct companies with different business objectives and opportunities [2]. Company Overview - Anaptys has a 20-year history of generating best-in-class antibodies, with notable successes including Jemperli and imsidolimab, which have positively impacted patient lives and generated financial collaborations [3]. Financial Performance - Jemperli has shown impressive commercial uptake over the past 12 months, with anticipated future growth contributing to a significant tiered royalty stack from GSK that benefits Anaptys [4].